- Alkem Lab’s 4th Quarter net income: 2.94 billion rupees.
- Last year’s net income for the same period: 709.8 million rupees.
- Analysts’ estimate for this quarter: 3.5 billion rupees.
- Revenue stood at 29.4 billion rupees, a 1.4% year-over-year increase.
- Analysts expected higher revenue: 31.95 billion rupees.
- Total costs decreased by 0.8% year-over-year to 26.4 billion rupees.
- Finance costs were 268.6 million rupees, a decrease of 7.3% year-over-year.
- Finance costs were higher than the estimated 203.3 million rupees.
- Employee benefits expenses rose slightly by 0.6% year-over-year to 5.06 billion rupees.
- These expenses were lower than the estimated 5.74 billion rupees.
- Other income increased significantly by 28% year-over-year, reaching 881.7 million rupees.
- Dividend per share declared: 5 rupees.
- Analyst recommendations: 11 buys, 8 holds, and 7 sells.
Alkem Laboratories Ltd on Smartkarma
Analysts on Smartkarma are bullish on Alkem Laboratories Ltd, according to Tina Banerjee‘s recent report titled “Alkem Laboratories Ltd (ALKEM IN): Further Upside on Card on US Business and Margin Improvement.” The report highlights Alkem’s expected high-single-digit growth in dollar terms from its US business in FY24, with a projected gross margin guidance of 59.0–59.5%. This positive outlook is supported by lower raw material costs and reduced price erosion in the US market. Alkem’s strong Q2 performance, with revenue growing 12% YoY and gross margin expanding to 61.4%, has driven a 23% rally in the company’s shares since early November, significantly outperforming the Nifty Pharma index.
A look at Alkem Laboratories Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alkem Laboratories Ltd, a pharmaceutical company, shows a promising long-term outlook based on the Smartkarma Smart Scores analysis. With a strong focus on resilience and dividends, scoring high at 5 and 4 respectively, the company demonstrates its stability and commitment to rewarding its investors. Additionally, Alkem scores reasonably well in growth and momentum, indicating a potential for future expansion and market activity.
Operating as a pharmaceutical company, Alkem Laboratories Limited engages in researching, developing, manufacturing, and marketing both generic and branded pharmaceuticals. The company’s diverse product portfolio also extends to nutraceuticals, functional foods, health foods, and herbal products, showcasing a broad range of offerings to meet various market demands.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
